Clearwater International Germany has advised the shareholders of CoGAP GmbH (CoGAP) on the sale of the majority of shares to R-Biopharm AG (R-Biopharm).
Founded in 2009, CoGAP is a highly innovative company specialised in genetic analysis for health optimisation. The company evaluates the latest discoveries within human genetics, and incorporates these into practical applications. CoGAP allows its customers to tailor their health care to their specific needs, and to select the optimal health care recommendations from the breadth of available health care advice.
Headquarted in Germany, R-Biopharm is a leading developer of test solutions for clinical diagnostics, plus food and feed analysis. In both sectors, the R-Biopharm test kits offer high precision and accuracy, key requirements when patient and consumer health is at risk.
The Clearwater International team was led by Managing Partner Dierk Rottmann, and Director Benjamin Bubrowski, with support from Analyst Manuel Erath.